PROVIDING HOPECorporate Social Responsibility • North America • 2012

AND THE PASSION TO M

John Spinnato Vice President • North American Corporate Social Responsibility • Sanofi US

AKE A DIFFERENCE

1

Welcome!

In 2011, Sanofi North American

Corporate Social Responsibility (CSR) delivered

many best practices and notable accomplishments

including:

• Formation of the Sanofi Patient Connection™

• The first ever Sanofi Volunteer Week

• A revised Social Investments Platform

• Formation of a North American CSR Network to help implement

CSR practices

At Sanofi, we have a passion for making a difference in patients’ lives, and to support

this effort by developing innovative new products, while taking into account how these

products are developed. We believe that CSR is an integral part of the process to bring

novel healthcare solutions to patients, including making ethical, social, and environmentally

responsible decisions that serve patients and the community.

We are committed to fully integrating CSR into our daily activities and mindset. In late 2010,

CSR became of such importance to Sanofi that a North American CSR organization was

put in place, and in 2011 the US Compliance Committee mission was expanded to oversee the

CSR Strategy. We will continue to engage stakeholders so that we can truly focus on what

is most important to us – providing innovative healthcare to those in need.

SANOFI IN NORTH AMERICA

Sanofi is a global and diversified health-

care leader which discovers, develops,

and distributes therapeutic solutions

focused on patients’ needs. In North

America, Sanofi has offices in the US,

in Canada and in Puerto Rico.

Sanofi has core strengths in the field of

healthcare with seven growth platforms:

diabetes solutions (Sanofi), human vac-

cines (Sanofi Pasteur), innovative drugs,

www.sanofi.us www.sanofi.ca

www.chattem.com www.chattem.ca

www.genzyme.com www.genzyme.ca

www.sanofipasteur.uswww.sanofipasteur.ca

www.merial.com www.merial.ca

rare diseases (Genzyme), consumer

healthcare (Chattem in the US), emerging

markets, and animal health (Merial). Sanofi

US is headquartered in Bridgewater, NJ.

www.sanofi.us

Net sales North America:

$14,628 million USD

Net sales global: $46,468 million USD

2011 total employees North America:

19,956

2

P A T I E N T

P E O P L E

E T H I C S

The patient at the center of our business

Our employees and communities

Our ethics in action

Our environmental performance

P L A N E T

3

We are a responsible company

with a culture of improving health and

providing hope that is fully integrated

with our strategic priorities,

bringing enhanced value to patients,

employees and other stakeholders.

OUR CORPORATE SOCIAL RESPONSIBILITY VISION

IMPROVING PATIENTS’ LIVES

Every day we act to improve access to medicines and healthcare, to promote prevention and wellness, to educate patients about diseases, as well as to support healthcare professionals. To this end, we engage in a continuing dialogue with patients, patient advocacy groups, and other stakeholders to discover innovative solutions for the challenges that patients face.

P A T I E N T

4

222,000 patients with free

drugs from Sanofi’s

patient assistance

program

5

3 million lives saved each

year thanks to

vaccinations

Access to Healthcare

Even in developed countries, such as the US

and Canada, patients have difficulties access-

ing treatment due to inadequate health care

coverage. Patients are our number one priority

… to meet their needs more effectively, Sanofi

US has developed an integrated patient sup-

port program called Sanofi Patient Connection,

a comprehensive program designed to assist

patients and healthcare professionals. Sanofi

Patient Connection offers a wide variety of

services across the US product portfolio, and

provides the utmost in access and support to

the patient as well as their healthcare team,

There are three main types of patient support

which connect them with the assistance and

resources they need:

• Reimbursement Connection – helps patients to

determine if they qualify for a prescription drug

insurance benefit

• Patient Assistance Connection – provides

free prescription drugs to patients who

do not have insurance coverage and

who meet eligibility criteria

• Resource Connection – helps patients

find additional resources and support

for their healthcare needs

Sanofi US also participates in the Pharma-

ceutical Research and Manufacturers of

America (PhRMA) Partnership for Prescription

Assistance (PPA) together with over 475 support

programs that provide free or nearly free medi-

cations to the underserved.

For more information: http://csr.sanofi.us

Educating Patients about Diseases

At Sanofi, we believe that our mission goes

beyond ensuring the availability of medicines.

By educating patients about disease, its

prevention, and treatments, Sanofi is promot-

ing a healthy way of life in order to reduce the

healthcare cost burden for patients and the

healthcare system.

In order to reach the broadest population, Sanofi

US patient education programs use different

materials and approaches to promote health

education. For example, we teamed up with the

National Basketball Association, the Women’s

National Basketball Association, the NBA

Development League, and the American

Diabetes Association (ADA) on a new national

multimedia campaign, Dribble to Stop Diabetes.

Together, we have planned basketball clinics

and created public service announcements to

raise fan awareness of diabetes and to

encourage people with diabetes to live

active, healthy lifestyles. For more

information: http://www.nba.com/

nbafit/stopdiabetes

At Sanofi, we believe that education

can dramatically impact the choices

that people make. Many diseases can

be prevented by vaccination.

However, there is a lot of

confusing information

being communicated

about immunizations,

and many parents

question the need to

vaccinate. In response,

Sanofi Pasteur felt

compelled to provide

balanced information

about vaccines and to

help families make informed

decisions. The ImmYounitySM

campaign provides accurate and

consumer-friendly science-based information

about immunization that can be easily accessed

at www.vaccines.com

New Services for Patients

Part of the Sanofi business strategy is to

provide a full range of healthcare options –

to go beyond drugs to meet the daily needs

of patients through services and devices. One

example is the iBGStar ®. It is a blood glucose

meter that was designed with patients in mind –

to allow them to seamlessly integrate accurate

blood glucose monitoring into their daily lives.

iBGStar® is the first and only FDA-cleared blood

glucose meter that directly connects to the

Apple® iPhone® and iPod touch®.

With the click of a mouse, consumers can ask

for a Customer Service representative to call

them, and the customer’s phone rings within

seconds of the request. This is thanks to another

technological tool developed for patients called

Click-to-Talk that enables Sanofi US to quickly

answer customer questions. Sanofi US is one of

only two major pharmaceutical companies that

have made this option available.

PARTNERING TO EDUCATE AND BUILD HEALTHIER COMMUNITIES

P E O P L E

6

We support the communities in which we work and live, as well as caring for one of our most important assets - our employees. All our locations throughout the US and Canada partner with and support our communities through a combination of social investments and community affairs activities.

Giving Back to Our Communities

Volunteerism is one of the pillars of the Sanofi

North American Social Investments initiative. In

2011, we decided to broaden our volunteerism

activities to include all Sanofi businesses and

functions in a North American effort spanning

29 sites. The event was so successful, that

the Sanofi Volunteer Week has become

an annual event.

Inspiring Students for Science

In order to encourage students’ interest in the

sciences, Sanofi supports science programs.

Genzyme Science Kids, a Massachusetts-based

program, engages students in local communities

through hands-on laboratory activities working

side-by-side with Genzyme scientists. In Canada,

the Sanofi BioGENEius Challenge Canada

(SBCC), a national biotechnology-focused science

competition, exposes high school, general and

vocational education college students to the

exciting field of biotechnology and the oppor-

tunities a career in the bio-economy might hold

for them. Since its inception, more than 4,000

national, provincial, and local organiza-

tions have partnered in this edu-

cational outreach. In addition,

Sanofi Pasteur US supports the

Biogenius Challenge within

the United States.

7

Over

6,938 patients’ lives

touched in 2011

in 2011,

Approximately 20,000

people worldwide

benefited from Sanofi

US’s disaster relief

assistance

Our Humanitarian Efforts

Building upon the Sanofi Espoir Foundation’s

worldwide humanitarian philosophies, North

American Social Investments is committed to

responsible business that includes, bringing

enhanced value to patients, employees and

other stakeholders, while improving life and

providing hope.

In the aftermath of a disaster and consistent

with World Health Organization principles, our

response may consist of donating medicines

and vaccines .

Our 2011 North American Social Investment

efforts included:

Sanofi US rallied for patients affected

by reportedly 305 deadly tornadoes

in the Southeast. This included our

Sanofi sales professionals driving

hours through tornado stricken areas

of Alabama to deliver hundreds of

insulin samples. Ten successful deliveries

were made within a critical 2.5 day

timeframe across some of the hardest

hit areas, first being the Children’s

Hospital in Birmingham, then to other

hard hit areas such as Huntsville and

Tuscaloosa.

On Friday, March 10, 2011, a pair of the

most deadly and catastrophic natural

disasters occurred in the country of Japan –

an earthquake measuring 9.0 triggered a

massive devastating tsunami. Sanofi immediately

announced a donation in the amount of one

million Euros (about 1.3 million US dollars). In

conjunction with Sanofi’s global relief program,

Sanofi US activated a special Japan Disaster re-

lief program for employees, whereby each dollar

donated would be matched dollar for dollar by

the company, raising an additional $122,043.00.

For more information: http://csr.sanofi.us

OPERATING OUR BUSINESSES ETHICALLY AND RESPONSIBLY

To ensure that our daily work is in the best interest of patients and the community, we follow the Sanofi Code of Ethics as well as regional codes such as the US Code of Business Conduct, a standard for ethical decision-making. Our employees adhere to these codes because the way we conduct business, how we approach innovation, and research and development, and how we produce and commercialize our products is just as important as the products and services themselves.

E T H I C S

8

5,091 patients living in

North America

included in 175 Sanofi

clinical trials

in 2011

9

Within the framework of Human Rights, Sanofi

has implemented a Responsible Procurement

program that is based on the Sanofi Supplier

Code of Conduct. This Code which is distrib-

uted to suppliers was developed to ensure that

all suppliers are aware of the Group’s CSR

principles. This code of conduct is a key

component of CSR for Sanofi and our

suppliers are required to comply

with it.

For more on Sanofi’s efforts

in implementing Responsible

Procurement regionally visit:

http://csr.sanofi.us

Sanofi US has been working

diligently to increase the

breadth and depth of its Supplier

Diversity program. We are dedicated

to ensuring that opportunities are avail

able to small, minority-owned, women-

owned, HubZone, disabled business

enterprises, as well as veteran and service-

disabled veteran-owned businesses.

Our Supplier Diversity Initiative:

• Brings value to our business as well as to the

communities in which we live and serve

• Reinforces our dedication to a small & diverse

supplier base

• Promotes continued innovation and

an entrepreneurial spirit which

also encourages economic

development.

For more information about

our Supplier Diversity Efforts:

http://csr.sanofi.us

Ethics in R&D

In North America, Sanofi sponsors clinical trails

through Sanofi Pharmaceuticals, Genzyme,

Fovea and Sanofi Pasteur, as well as ventures

with government organizations, other pharma-

ceutical companies and biotech firms. All clinical

trials are conducted in compliance with strict

ethics and quality regulations including those

issued by the Food and Drug Administration

Sanofi believes in transparent medical research

and provides healthcare professionals and

patients with the information they need

about our R&D projects and products,

which helps to make informed

medical decisions.

Sanofi US follows the Sanofi

Charter for the Humane Care

and Use of Laboratory Animals.

This charter, established in

2006, adheres to the 3R’s principle

(Reduction/Replacement/Refinement).

In addition, the Culture of Care

Program, which originated in our US

affiliate, has been implemented in

other countries.

In addition, Sanofi Bridgewater

R&D developed its own dog

adoption policy that covers

any dog used for research.

The site has an agreement with

a non-profit organization called the

Beagle Rescue League that finds

homes for dogs retiring from research

facilities.

For more information about the Beagle

Rescue League click on the following link:

http://www.beaglerescueleague.org/

Responsible Procurement/ Supply Chain

Respect for Human Rights forms the foundation

upon which our corporate social responsibility

policy is built. When we deal with suppliers, we

are governed by local legislation, our internal

policies, and our standards in terms of human

rights, labor, environment, and ethical conduct.

Approximately

3,000 - the number of small

& diverse suppliers

contracted

in 2011

SUSTAINING A HEALTHY PLANET FOR THE PATIENT

Thirteen million deaths can be prevented every year by safeguarding our environment. Sanofi strongly contributes to protecting the planet that is our shared home. We have instituted an ambitious policy to reduce the environmental impact of our operations and to defend public health.

P L A N E T

10

water consumption by approximately 2 million

gallons per year and 10% of water costs despite

a 300% rate increase the water supplier.

At our Swiftwater, Pennsylvania site, a high-quality,

cold water fishery stream, Swiftwater Creek,

traverses the plant. Analyses were performed

on various strategies to manage and treat future

effluents from the plant based on recent increas-

es in vaccine production. To address this, the

site combined an array of innovative treatment

technologies (UV, ozone) using membrane

separation and carbon adsorption. Water is

treated and tested, and when it leaves the plant,

it is capable of being safely discharged into

the environment.

Multi-dose Medication Dispensing for Discharge

Pharmaceuticals in the Environment (PIE) is an

issue in the pharmaceutical industry. Sanofi is

working with many pharmaceutical organizations

to perform testing on our products to assure

they have little or no impact on the environment.

In addition, some regions are partnering with

other organizations to make and impact at a

different part of the treatment life cycle. Here is

an example from the US:

Hospital patients using medications dispensed

in multi-dose containers (e.g., insulin pens,

asthma inhalers) often need to continue these

medications upon discharge. However, surveys

show that in approximately 50% of US hospitals

partially-used, multi-dose containers are dis-

carded upon discharge, and the patient is given

a new prescription to be filled at a community

pharmacy. In addition to resulting in unneces-

sary costs for the patient and the healthcare

system, this practice produces substantial phar-

maceutical waste. Sanofi US partnered with the

American Society of Health System Pharmacists

(ASHP), to promote awareness, including live

programming and reference resources, and a

comprehensive web-based toolkit to facilitate

implementation of a program to reduce medica-

tion waste. The results: one hospital in Michigan

demonstrated a 50% reduction in medication

waste after the implementation of this program.

For more information: www.multidose.org

For more information about our environmental

initiatives: http://csr.sanofi.us

15 LEED certified sites

in North America

11

Climate Change

Climate change affects health by impacting

clean air, potable water, sufficient food and

secure shelter. Deaths are caused by climate

sensitive conditions such as gastrointestinal

diseases (2.2 million deaths per year), malnutri-

tion (3.5 million), malaria (900,000) and dengue.

Minimizing Green House Gas (GHG) emissions

can contribute significantly to preventing these

disease types from impacting new areas of

our planet.

In order to reduce our impact on climate change,

we seek to limit our carbon footprint by reducing

energy consumption and minimizing GHG emis-

sions. For example, in North America, reduction

in energy consumption resulted in decreases for

both direct and indirect CO2 emissions of 7.6%

and 19% respectively from 2010 to 2011.

A few of our regional activities that are now help-

ing us to limit our carbon footprint include:

• Lighting upgrades, renewable energy

use, van/carpooling, telecommuting,

reduced HVAC air changes, com-

pressed air leak repairs are examples

of actions taking place at Sanofi,

Genzyme and Merial sites in the US

and in Canada

• The Genzyme site based in Allston MA

installed a combined heat & power system

that will save $1.5 million/year in energy costs,

reduce GHG emissions by 1,600 tons carbon,

and generate Alternative Portfolio Standard

(APS) revenue of up to $200,000/year

Preserving Water and its Sources

Clean water management has become one of

the most important issues of the 21st century. In

addition to reducing water consumption, Sanofi

focuses on preserving natural water resources.

Here are two examples of our efforts:

Since 2008, our Merial headquarters site in

Georgia, instituted a GreenSite program.

Included in this program was an effort to reduce

water consumption. Some of the methods em-

ployed at the site included moving from standard

landscaping to xeriscaping, prescribing vigilant

preventative maintenance for interior plumbing,

as well as training employees to help conserve

water. The results were impressive – reduction of

SANOFI RECOGNITION

In 2011, Sanofi was once again listed on

the most important global indices for CSR

performance.

About Sanofi North American Corporate Social Responsibility –

During the past year, North American CSR delivered best practices

for Sanofi sites in the US and Canada. The information provided here

covers the calendar year 2011 unless otherwise specified.

We invite your feedback. Please send us your thoughts at:

nacsr@sanofi.com

12

Among the top 5

AND THE PASSION TO M

© 2012 sanofi-aventis U.S. LLC, a Sanofi CompanyUS.COR.12.06.003

Environmental Attributes:

Contains FSC certified 100% post consumer fiber. Certified EcoLogo, processed chlorine free and FSC recycled. Manufactured using Biogas energy.

FPOPlace-holder

Designed and printed by small business owners:

Design & Editorial Review: Big Arrow Group, New York

Printing: Paravista, Inc.

Sanofi discovers, develops and distributes therapeutic solutions focused on patients’ needs.

Sanofi US • 55 Corporate Drive • Bridgewater, NJ • 08807 • http://csr.sanofi.us